Price Alert

Cidara Therapeutics Inc. (CDTX)

NASDAQ: CDTX · Real-Time Price · USD

64.78

1.23 (1.94%)

At close: Aug 15, 2025, 12:49 PM

1.94% (1D)

Bid	63.94
Market Cap	1.64B
Revenue (ttm)	302K
Net Income (ttm)	-180.73M
EPS (ttm)	-7.63
PE Ratio (ttm)	-8.49
Forward PE	-8.54
Analyst	Strong Buy

Ask	65.41
Volume	206,401
Avg. Volume (20D)	736,212
Open	63.76
Previous Close	63.55
Day's Range	62.15 - 64.78
52-Week Range	10.14 - 66.94
Beta	1.19

About CDTX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CDTX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CDTX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

+113.84%

Cidara Therapeutics shares are trading higher afte... Unlock content with Pro Subscription

8 months ago

+15.41%

Cidara Therapeutics shares are trading higher. The company announced a $105 million private placement.

News

1 week ago · seekingalpha.com

Cidara Therapeutics, Inc. (CDTX) Q2 2025 Earnings Call Transcript

Cidara Therapeutics, Inc. (NASDAQ:CDTX ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Frank L. Karbe - Chief Financial Officer Jeffrey L.

1 week ago · fool.com

Cidara (CDTX) Q2 Cash Surges 163%

1 month ago · businesswire.com

Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics

MIAMI LAKES, Fla.--(BUSINESS WIRE)-- #AntiviralTreatment--Segal Trials proudly announces its participation in the successful Phase 2b NAVIGATE clinical trial conducted by Cidara Therapeutics, evaluati...

1 month ago · marketbeat.com

Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains

The biopharmaceuticals space is notorious for sudden, sharp rallies, and for precipitous sell-offs as well. The industry is crowded with names, many of which are tiny firms working toward developing a...

1 month ago · seekingalpha.com

Cidara Therapeutics Advances CD388 To Phase 3, Reiterate Buy

Cidara Therapeutics' main value driver, CD388, recently achieved an impressive 76% protection in its Phase 2b trials. It also showed a compelling safety profile. In my view, CD388 now has a clear path...

1 month ago · benzinga.com

Why Is Cidara Therapeutics Stock Trading Higher On Monday?

Cidara Therapeutics, Inc. CDTX stock is trading over 90% higher on Monday with a session volume of 3.2 million compared to the average volume of 181.7K.

2 months ago · seekingalpha.com

Cidara Therapeutics: All Stars Aligning In Favor Of CD388

Cidara Therapeutics' CD388 is a long-acting influenza antiviral aimed at providing universal protection with a single yearly dose for each flu season. In contrast to vaccines, CD388's efficacy is not ...